EAU 2021 | Benefits of T1 substaging for NMIBC

Christiaan De Jong, MD, Erasmus University Medical Center, Rotterdam, The Netherlands, gives an overview of the benefits of T1 substaging of patients with non-muscle invasive bladder cancer (NMIBC) to identify patients who are at a high risk of progression after Bacillus Calmette-Guérin (BCG) therapy, and to identify optimal candidates for BCG therapy. Dr De Jong comments on a risk stratification model developed by the European Association of Urology (EAU) and describes the known benefits of substaging, as well as highlighting the need for larger studies. Dr De Jong also talks on the findings of a study which analyzed genomic data from 700 patients with BCG-treated T1 high-grade bladder cancer. This interview took place at the virtual EAU Virtual Meeting 2021.